VMD · Viemed Healthcare, Inc.

Viemed’s Q1 2026 results reflect strong execution against its strategic pivot toward less capital-intensive, higher-margin service lines—particularly PAP therapy and maternal health—while maintaining stability in its core ventilator business. Revenue growth of 28% YoY was driven by a 57% YoY increase in PAP therapy patients and a 42% rise in new patient starts, underscoring improved commercial traction and clinical scalability. Though gross margin held steady at 57%, the shift in revenue mix—from 54% rental in Q1 2025 to 68% rental in Q1 2026—was partially offset by higher sales & service revenue (23.2% of total vs. 12.7% YoY), which carries lower capital intensity but also lower margins. Adjusted EBITDA grew 12% YoY to $14.3 million, but management explicitly noted the prior-year period benefited from a $2.7 million non-recurring gain on ventilator equipment disposal, implying underlying operational improvement is stronger than headline growth suggests. The company generated $2.6 million in free cash flow during the quarter—despite $6.7 million in capex—reflecting disciplined working capital management and reduced equipment turnover needs. With $46 million in undrawn credit capacity and effectively no net debt, Viemed’s balance sheet supports continued capital return (evidenced by $1.4 million in share repurchases) and organic investment. CEO Casey Hoyt emphasized that the combination of diversified growth, capital efficiency, and durable free cash flow represents a structural inflection—not just cyclical outperformance—positioning investors to reassess valuation relative to historical home medical equipment peers.